NASDAQ:CYTKCytokinetics Stock Price, Forecast & News

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CYTK shares have increased by 82.2% and is now trading at $21.92.
View which stocks have been most impacted by COVID-19.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cytokinetics.

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Cytokinetics.

Cytokinetics, Inc. (NASDAQ:CYTK) released its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by $0.11. The biopharmaceutical company had revenue of $3.59 million for the quarter, compared to analyst estimates of $4.80 million.
View Cytokinetics' earnings history.

Cytokinetics issued an update on its FY 2020 After-Hours earnings guidance on Thursday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $18-22 million, compared to the consensus revenue estimate of $24.38 million.

9 Wall Street analysts have issued twelve-month target prices for Cytokinetics' shares. Their forecasts range from $20.00 to $59.00. On average, they anticipate Cytokinetics' stock price to reach $37.22 in the next year. This suggests a possible upside of 69.8% from the stock's current price.
View analysts' price targets for Cytokinetics.

Press coverage about CYTK stock has trended extremely negative on Thursday, according to InfoTrie. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cytokinetics earned a news impact score of -4.1 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.
View the latest news about Cytokinetics.

Some companies that are related to Cytokinetics include Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR), Zai Lab (ZLAB), HUTCHISON CHINA/S (HCM), Schrodinger (SDGR), Allakos (ALLK), Blueprint Medicines (BPMC), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), FibroGen (FGEN), Legend Biotech (LEGN), HYPERA S A/S (HYPMY), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Arena Pharmaceuticals (ARNA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), TherapeuticsMD (TXMD), AbbVie (ABBV) and Dynavax Technologies (DVAX).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wasatch Advisors Inc. (4.81%), Bank of New York Mellon Corp (1.10%), Jennison Associates LLC (1.04%), Principal Financial Group Inc. (0.78%), Asymmetry Capital Management L.P. (0.35%) and Barclays PLC (0.22%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Mark A Schlossberg, Robert I Blum, Sandford D Smith, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga.
View institutional ownership trends for Cytokinetics.

CYTK stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Hudson Bay Capital Management LP, ClariVest Asset Management LLC, SG Americas Securities LLC, Russell Investments Group Ltd., Trexquant Investment LP, UBS Group AG, and Virtus ETF Advisers LLC. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Fady Ibraham Malik, Mark A Schlossberg, Robert I Blum, Sandford D Smith, Santo J Costa, and Wendall Wierenga.
View insider buying and selling activity for Cytokinetics.

CYTK stock was bought by a variety of institutional investors in the last quarter, including EAM Investors LLC, Barclays PLC, Bank of New York Mellon Corp, New York State Teachers Retirement System, Aigen Investment Management LP, Rafferty Asset Management LLC, Swiss National Bank, and Teza Capital Management LLC. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Cytokinetics.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CYTK stock can currently be purchased for approximately $21.92.

Cytokinetics has a market capitalization of $1.30 billion and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.

The official website for Cytokinetics is www.cytokinetics.com.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]